Imunon (IMNN) Competitors $0.84 -0.04 (-4.71%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNN vs. RPTX, BDRX, ONCY, PEPG, IMRX, PDSB, SKYE, GANX, ICCC, and CUEShould you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Repare Therapeutics (RPTX), Biodexa Pharmaceuticals (BDRX), Oncolytics Biotech (ONCY), PepGen (PEPG), Immuneering (IMRX), PDS Biotechnology (PDSB), Skye Bioscience (SKYE), Gain Therapeutics (GANX), ImmuCell (ICCC), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry. Imunon vs. Repare Therapeutics Biodexa Pharmaceuticals Oncolytics Biotech PepGen Immuneering PDS Biotechnology Skye Bioscience Gain Therapeutics ImmuCell Cue Biopharma Imunon (NASDAQ:IMNN) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings. Does the MarketBeat Community believe in IMNN or RPTX? Repare Therapeutics received 20 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 64.18% of users gave Repare Therapeutics an outperform vote. CompanyUnderperformOutperformImunonOutperform Votes23100.00% Underperform VotesNo VotesRepare TherapeuticsOutperform Votes4364.18% Underperform Votes2435.82% Do institutionals & insiders have more ownership in IMNN or RPTX? 4.5% of Imunon shares are held by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are held by institutional investors. 5.0% of Imunon shares are held by insiders. Comparatively, 21.6% of Repare Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is IMNN or RPTX more profitable? Imunon has a net margin of 0.00% compared to Repare Therapeutics' net margin of -99.76%. Repare Therapeutics' return on equity of -40.87% beat Imunon's return on equity.Company Net Margins Return on Equity Return on Assets ImunonN/A -230.05% -128.98% Repare Therapeutics -99.76%-40.87%-35.07% Do analysts rate IMNN or RPTX? Imunon presently has a consensus target price of $21.50, suggesting a potential upside of 2,459.52%. Repare Therapeutics has a consensus target price of $4.50, suggesting a potential upside of 228.47%. Given Imunon's stronger consensus rating and higher probable upside, equities analysts plainly believe Imunon is more favorable than Repare Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Imunon 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable earnings and valuation, IMNN or RPTX? Imunon has higher earnings, but lower revenue than Repare Therapeutics. Repare Therapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImunon$500K24.56-$19.51M-$1.60-0.53Repare Therapeutics$53.48M1.09-$93.80M-$2.00-0.69 Which has more volatility & risk, IMNN or RPTX? Imunon has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Does the media favor IMNN or RPTX? In the previous week, Imunon had 1 more articles in the media than Repare Therapeutics. MarketBeat recorded 2 mentions for Imunon and 1 mentions for Repare Therapeutics. Imunon's average media sentiment score of 1.28 beat Repare Therapeutics' score of 0.94 indicating that Imunon is being referred to more favorably in the media. Company Overall Sentiment Imunon Positive Repare Therapeutics Positive SummaryImunon beats Repare Therapeutics on 12 of the 18 factors compared between the two stocks. Get Imunon News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNN vs. The Competition Export to ExcelMetricImunonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.28M$6.89B$5.57B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.447.4422.4418.48Price / Sales24.56242.70394.09103.59Price / CashN/A65.8538.1834.62Price / Book0.596.516.774.25Net Income-$19.51M$143.21M$3.22B$248.23M7 Day Performance-6.27%1.98%1.49%0.89%1 Month Performance-20.38%6.89%4.00%3.53%1 Year Performance-35.88%-2.52%16.21%5.08% Imunon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNNImunon2.6946 of 5 stars$0.84-4.7%$21.50+2,459.5%-35.9%$12.28M$500,000.00-0.4430Short Interest ↓Positive NewsGap DownRPTXRepare Therapeutics3.3579 of 5 stars$1.20flat$4.50+275.0%-55.8%$51.01M$53.48M-0.60180Upcoming EarningsBDRXBiodexa Pharmaceuticals0.4316 of 5 stars$1.38-3.5%N/AN/A$50.43M$83,000.000.0020ONCYOncolytics Biotech1.5523 of 5 stars$0.58+2.5%$4.33+653.6%-48.6%$49.69MN/A-2.1330Upcoming EarningsPEPGPepGen2.9105 of 5 stars$1.52+14.3%$10.33+579.8%-87.2%$49.69MN/A-0.5130IMRXImmuneering3.7712 of 5 stars$1.38+8.7%$12.50+805.8%-16.2%$49.52M$320,000.00-0.7060Upcoming EarningsShort Interest ↓News CoveragePositive NewsGap DownPDSBPDS Biotechnology1.5197 of 5 stars$1.08flat$9.00+733.3%-58.2%$49.03MN/A-0.9320SKYESkye Bioscience1.3381 of 5 stars$1.57+9.4%$16.60+957.3%-83.1%$48.63MN/A-2.1811GANXGain Therapeutics3.0331 of 5 stars$1.74-3.3%$8.20+371.3%-30.0%$48.35M$50,000.00-1.5820News CoverageICCCImmuCell0.9573 of 5 stars$5.38-2.2%N/A+10.4%$48.33M$26.49M-10.7670CUECue Biopharma4.2229 of 5 stars$0.78+2.5%$3.00+284.0%-60.3%$48.29M$9.29M-0.8760Upcoming EarningsPositive News Related Companies and Tools Related Companies RPTX Competitors BDRX Competitors ONCY Competitors PEPG Competitors IMRX Competitors PDSB Competitors SKYE Competitors GANX Competitors ICCC Competitors CUE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Imunon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Imunon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMNN Stock Free IMNN Stock Alerts